Download PDF
Neuropediatrics 2021; 52(05): 358-369
DOI: 10.1055/s-0040-1722691
Original Article

The outcome of 41 Late-Diagnosed Turkish GA-1 Patients: A Candidate for the Turkish NBS

Sebile Kılavuz 
1   Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
,
Derya Bulut 
1   Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
,
Deniz Kor 
1   Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
,
Berna Şeker-Yılmaz 
2   Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Mersin University Faculty of Medicine, Mersin, Turkey
,
Neslihan Özcan 
3   Division of Pediatric Neurology, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
,
Faruk Incecik 
3   Division of Pediatric Neurology, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
,
Bilen Onan 
4   Department of Radiology, Çukurova University Faculty of Medicine, Adana, Turkey
,
Gülay Ceylaner 
5   Department of Medical Genetics, Intergen Genetics Centre, Ankara, Turkey
,
Neslihan Önenli-Mungan 
1   Division of Pediatric Nutrition and Metabolism, Department of Pediatrics, Çukurova University Faculty of Medicine, Adana, Turkey
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Background Glutaric aciduria type 1(GA-1) is an inherited cerebral organic aciduria. Untreated patients with GA-1 have a risk of acute encephalopathic crises during the first 6 years of life. In so far as GA-1 desperately does not exist in Turkish newborn screening (NBS) program, most patients in our study were late-diagnosed.

Method This study included 41 patients diagnosed with acylcarnitine profile, urinary organic acids, mutation analyses in the symptomatic period. We presented with clinical, neuroradiological, and molecular data of our 41 patients.

Results The mean age at diagnosis was 14.8 ± 13.9 (15 days to 72 months) and, high blood glutaconic acid, glutarylcarnitine and urinary glutaric acid (GA) levels in 41 patients were revealed. Seventeen different mutations in the glutaryl-CoA dehydrogenase gene were identified, five of which were novel. The patients, most of whom were late-diagnosed, had a poor neurological outcome. Treatment strategies made a little improvement in dystonia and the frequency of encephalopathic attacks.

Conclusion All GA-1 patients in our study were severely affected since they were late-diagnosed, while others show that GA-1 is a treatable metabolic disorder if it is diagnosed with NBS. This study provides an essential perspective of the severe impact on GA-1 patients unless it is diagnosed with NBS. We immediately advocate GA-1 to be included in the Turkish NBS.

Keywords

glutaric aciduria type 1 - acute encephalopathic crises - newborn screening program - dystonia

Ethics Committee Approval

The study was approved by the Ethics in Research Committee of Çukurova University Faculty of Medicine, Adana, Turkey (approval number: 2019/85–58).


Informed Consent

Consent form was filled out by all participants.


Authors' Contributions

N.Ö.-M., S.K., and B.Ş.Y. contributed toward surgical and medical practices, S.K., N.Ö.-M., and D.B. developed the concept. S.K. and D.K. designed the study. N.Ö.-M., S.K., F.İ., N.Ö., and B.O. contributed toward data collection and processing. N.Ö.-M., S.K., and G.C. did the data analysis and interpretation. D.B., S.K., and D.K. searched the literature and S.K. did the writing. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.


Financial Disclosure

The authors declare that this study received no financial support.


Employment or Leadership

None declared.


Honorarium

None declared.




Publication History

Received: 23 May 2020

Accepted: 28 September 2020

Article published online:
12 February 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Baric I, Wagner L, Feyh P, Liesert M, Buckel W, Hoffmann GF. Sensitivity and specificity of free and total glutaric acid and 3-hydroxyglutaric acid measurements by stable-isotope dilution assays for the diagnosis of glutaric aciduria type I. J Inherit Metab Dis 1999; 22 (08) 867-881
    CrossrefPubMedGoogle Scholar
  • 2 Kyllerman M, Skjeldal OH, Lundberg M. et al. Dystonia and dyskinesia in glutaric aciduria type I: clinical heterogeneity and therapeutic considerations. Mov Disord 1994; 9 (01) 22-30
    CrossrefPubMedGoogle Scholar
  • 3 Kölker S, Garbade SF, Greenberg CR. et al. Natural history, outcome, and treatment efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2006; 59 (06) 840-847
    CrossrefPubMedGoogle Scholar
  • 4 Herskovitz M, Goldsher D, Sela BA, Mandel H. Subependymal mass lesions and peripheral polyneuropathy in adult-onset glutaric aciduria type I. Neurology 2013; 81 (09) 849-850
    CrossrefPubMedGoogle Scholar
  • 5 Kölker S, Valayannopoulos V, Burlina AB. et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis 2015; 38 (06) 1059-1074
    CrossrefPubMedGoogle Scholar
  • 6 Renaud DL. Leukoencephalopathies associated with macrocephaly. Semin Neurol 2012; 32 (01) 34-41
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Bjugstad KB, Goodman SI, Freed CR. Age at symptom onset predicts severity of motor impairment and clinical outcome of glutaric acidemia type 1. J Pediatr 2000; 137 (05) 681-686
    CrossrefPubMedGoogle Scholar
  • 8 Hoffmann GF, Athanassopoulos S, Burlina AB. et al. Clinical course, early diagnosis, treatment, and prevention of disease in glutaryl-CoA dehydrogenase deficiency. Neuropediatrics 1996; 27 (03) 115-123
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Boy N, Mühlhausen C, Maier EM. et al; Additional individual contributors. Proposed recommendations for diagnosing and managing individuals with glutaric aciduria type I: second revision. J Inherit Metab Dis 2017; 40 (01) 75-101
    CrossrefPubMedGoogle Scholar
  • 10 Kölker S, Garbade SF, Boy N. et al. Decline of acute encephalopathic crises in children with glutaryl-CoA dehydrogenase deficiency identified by newborn screening in Germany. Pediatr Res 2007; 62 (03) 357-363
    CrossrefPubMedGoogle Scholar
  • 11 Kölker S, Christensen E, Leonard JV. et al. Diagnosis and management of glutaric aciduria type I--revised recommendations. J Inherit Metab Dis 2011; 34 (03) 677-694
    CrossrefPubMedGoogle Scholar
  • 12 Hoffmann GF, Trefz FK, Barth PG. et al. Glutaryl-coenzyme A dehydrogenase deficiency: a distinct encephalopathy. Pediatrics 1991; 88 (06) 1194-1203
    CrossrefPubMedGoogle Scholar
  • 13 Heringer J, Boy SP, Ensenauer R. et al. Use of guidelines improves the neurological outcome in glutaric aciduria type I. Ann Neurol 2010; 68 (05) 743-752
    CrossrefPubMedGoogle Scholar
  • 14 American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system—executive summary. Pediatrics 2006; 117 (5 Pt 2): S296-S307
    CrossrefPubMedGoogle Scholar
  • 15 Strauss KA, Brumbaugh J, Duffy A. et al. Safety, efficacy and physiological actions of a lysine-free, arginine-rich formula to treat glutaryl-CoA dehydrogenase deficiency: focus on cerebral amino acid influx. Mol Genet Metab 2011; 104 (1-2): 93-106
    CrossrefPubMedGoogle Scholar
  • 16 Beauchamp MH, Boneh A, Anderson V. Cognitive, behavioural and adaptive profiles of children with glutaric aciduria type I detected through newborn screening. J Inherit Metab Dis 2009; 32 (Suppl. 01) S207-S213
    CrossrefPubMedGoogle Scholar
  • 17 Canda E, Yazc H, Er E. et al. Glutaric aciduria type I diagnosis case with normal glutaryl carnitine and urine organic acid analysis. J Pediatr Res 2017; 4 (05) 60-62
    PubMedGoogle Scholar
  • 18 Christensen E, Ribes A, Merinero B, Zschocke J. Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (06) 861-868
    CrossrefPubMedGoogle Scholar
  • 19 Kölker S, Ramaekers VT, Zschocke J, Hoffmann GF. Acute encephalopathy despite early therapy in a patient with homozygosity for E365K in the glutaryl-coenzyme A dehydrogenase gene. J Pediatr 2001; 138 (02) 277-279
    CrossrefPubMedGoogle Scholar
  • 20 Chalmers RA, Bain MD, Zschocke J. Riboflavin-responsive glutaryl CoA dehydrogenase deficiency. Mol Genet Metab 2006; 88 (01) 29-37
    CrossrefPubMedGoogle Scholar
  • 21 Gokmen-Ozel H, MacDonald A, Daly A. et al. Dietary practices in glutaric aciduria type 1 over 16 years. J Hum Nutr Diet 2012; 25 (06) 514-519
    CrossrefPubMedGoogle Scholar
  • 22 Bijarnia S, Wiley V, Carpenter K, Christodoulou J, Ellaway CJ, Wilcken B. Glutaric aciduria type I: outcome following detection by newborn screening. J Inherit Metab Dis 2008; 31 (04) 503-507
    CrossrefPubMedGoogle Scholar
  • 23 Boneh A, Beauchamp M, Humphrey M, Watkins J, Peters H, Yaplito-Lee J. Newborn screening for glutaric aciduria type I in Victoria: treatment and outcome. Mol Genet Metab 2008; 94 (03) 287-291
    CrossrefPubMedGoogle Scholar
  • 24 Kölker S, Christensen E, Leonard JV. et al. Guideline for the diagnosis and management of glutaryl-CoA dehydrogenase deficiency (glutaric aciduria type I). J Inherit Metab Dis 2007; 30 (01) 5-22
    CrossrefPubMedGoogle Scholar
  • 25 Mühlhausen C, Hoffmann GF, Strauss KA. et al. Maintenance treatment of glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27 (06) 885-892
    CrossrefPubMedGoogle Scholar
  • 26 Lütcherath V, Waaler PE, Jellum E, Wester K. Children with bilateral temporal arachnoid cysts may have glutaric aciduria type 1 (GAT1); operation without knowing that may be harmful. Acta Neurochir (Wien) 2000; 142 (09) 1025-1030
    CrossrefPubMedGoogle Scholar
  • 27 Garbade SF, Greenberg CR, Demirkol M. et al. Unravelling the complex MRI pattern in glutaric aciduria type I using statistical models-a cohort study in 180 patients. J Inherit Metab Dis 2014; 37 (05) 763-773
    CrossrefPubMedGoogle Scholar
  • 28 Kurkina MV, Mihaylova SV, Baydakova GV. et al. Molecular and biochemical study of glutaric aciduria type 1 in 49 Russian families: nine novel mutations in the GCDH gene. Metab Brain Dis 2020; 35 (06) 1009-1016
    CrossrefPubMedGoogle Scholar
  • 29 Zschocke J, Quak E, Guldberg P, Hoffmann GF. Mutation analysis in glutaric aciduria type I. J Med Genet 2000; 37 (03) 177-181
    CrossrefPubMedGoogle Scholar
  • 30 Isik E, Onay H, Atik T. et al. Clinical utility of a targeted next generation sequencing panel in severe and pediatric onset Mendelian diseases. Eur J Med Genet 2019; 62 (10) 103725
    CrossrefPubMedGoogle Scholar
  • 31 Busquets C, Soriano M, de Almeida IT. et al. Mutation analysis of the GCDH gene in Italian and Portuguese patients with glutaric aciduria type I. Mol Genet Metab 2000; 71 (03) 535-537
    CrossrefPubMedGoogle Scholar
  • 32 Goodman SI, Stein DE, Schlesinger S. et al. Glutaryl-CoA dehydrogenase mutations in glutaric acidemia (type I): review and report of thirty novel mutations. Hum Mutat 1998; 12 (03) 141-144
    CrossrefPubMedGoogle Scholar
  • 33 Boy N, Heringer J, Brackmann R. et al. Extrastriatal changes in patients with late-onset glutaric aciduria type I highlight the risk of long-term neurotoxicity. Orphanet J Rare Dis 2017; 12 (01) 77
    CrossrefPubMedGoogle Scholar
  • 34 Naughten ER, Mayne PD, Monavari AA, Goodman SI, Sulaiman G, Croke DT. Glutaric aciduria type I: outcome in the Republic of Ireland. J Inherit Metab Dis 2004; 27 (06) 917-920
    CrossrefPubMedGoogle Scholar
  • 35 Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am J Med Genet C Semin Med Genet 2003; 121C (01) 38-52
    CrossrefPubMedGoogle Scholar